APTITUDE HEALTH®

EPICS

EPICS CONGRESS COVERAGE: EHA 2020 – FOCUS ON LEUKEMIA AND MDS

June 2020

BACKGROUND

EPICS

- On June 15, 2020, during the 25th EHA Virtual Congress, Aptitude Health convened a group of experts in MDS, AML, and ALL to a small closed-session panel
- The goal of the panel was to discuss recent select studies presented at the EHA conference on acute leukemia and MDS, and their possible impact on real-world clinical practice

MEET THE EXPERTS . . .

EPICS

CO-CHAIR

Elias Jabbour, MD
MD Anderson Cancer Center
Houston, USA

CO-CHAIR

Dieter Hölzer, MD, PhD
Internal Medicine, University of Frankfurt
Frankfurt, Germany

FACULTY

Daniel DeAngelo, MD, PhD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, USA

Josep Maria Ribera, MD, PhD
ICO-Hospital Germans Trias i Pujol
Josep Carreras Leukemia Research Institute
Universitat Autònoma de Barcelona
Barcelona, Spain

Naval Daver, MD
MD Anderson Cancer Center
Houston, USA

Valeria Santini, MD
University of Florence
Florence, Italy

Gert Ossenkoppele, MD, PhD
VU University Medical Center
Amsterdam, the Netherlands

Jorge Sierra, MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain

AGENDA

EPICS

Time	Topic	Speaker/Moderator
5 min	Welcome and Introductions	Elias Jabbour, MD
10 min	**MDS**	Valeria Santini, MD
15 min	Discussion	All
5 min	*Key Takeaways*	Valeria Santini, MD; Elias Jabbour, MD
10 min	**Elderly/Unfit AML Patients**	Gert Ossenkoppele, MD, PhD
20 min	Discussion	All
5 min	*Key Takeaways*	Gert Ossenkoppele, MD, PhD; Elias Jabbour, MD
10 min	***IDH*- and *FLT3*-Mutant AML Patients**	Jorge Sierra, MD, PhD
15 min	Discussion	All
5 min	*Key Takeaways*	Jorge Sierra, MD, PhD; Elias Jabbour, MD
10 min	**BREAK**	All
10 min	**Emerging Immune Therapies in AML**	Naval Daver, MD
15 min	Discussion	All
5 min	*Key Takeaways*	Naval Daver, MD; Elias Jabbour, MD
10 min	**Updates in ALL**	Josep Maria Ribera, MD, PhD
20 min	Discussion	All
5 min	*Key Takeaways*	Josep Maria Ribera, MD, PhD; Dieter Hölzer, MD, PhD
5 min	Summary and Closing Remarks	Dieter Hölzer, MD, PhD

APTITUDE HEALTH®

EPICS

MDS

Presenter: Valeria Santini, MD

Moderator: Elias Jabbour, MD

MDS: SELECTED ABSTRACTS (1/5)

S182: PEVONEDISTAT (PEVO) PLUS AZACITIDINE (AZA) vs AZA IN PATIENTS (pts) with HIGH-RISK MDS L. Ades, et al

EPICS

Background

> Phase II randomized study of PEVO (first small-molecule inhibitor of the NEDD8-activating enzyme) plus AZA vs AZA in high-

MDS: SELECTED ABSTRACTS (2/5)

S183: IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) U. Platzbecker, et al

Background

- Phase II/III study of imetelstat (first-in-class oligonucleotide telomerase competitive inhibitor). Phase II

MDS: SELECTED ABSTRACTS (3/5)

S185: ANTI-TIM-3 ANTIBODY MBG453 IN COMBINATION WITH HYPOMETHYLATING AGENTS (HMAs) IN PTS WITH HIGH-RISK MDS U. Borate, et al

Background

- Phase Ib dose-escalation study to evaluate MBG453 (high-affinity humanized IgG monoclonal antibody

MDS: SELECTED ABSTRACTS (4/5)

S187: ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN MDS PATIENTS S. David, et al

Background

- Phase Ib study to determine the safety and efficacy of magrolimab (IgG monoclonal antibody against CD47, a “do not eat me”

MDS: SELECTED ABSTRACTS (5/5)

S188: VENETOCLAX PLUS AZA FOR THE TREATMENT OF R/R MDS PATIENTS

A.M. Zeidan, et al

Background

- Phase I study evaluating the safety and efficacy of VEN in combination with AZA in R/R MDS pts

mCR, marrow CR; PR, partial remisson.

MDS: DISCUSSION (1/3)

EPICS

Treatment combinations with HMAs for high-risk MDS pts

Combination therapies of HMA with inhibitors and/or antibodies to treat newly diagnosed and/or R/R MDS pts

MDS: DISCUSSION (2/3)

EPICS

Double- or triple-combination therapies? (cont)

MDS: DISCUSSION (3/3)

EPICS

Treatment sequence for high-risk MDS pts (cont)

TP53-mutant MDS pts

- AZA plus magrolimab or AZA plus APR-246 were indicated as possible treatments for *TP53*-mutant pts by some

APTITUDE HEALTH®

EPICS

Elderly/Unfit AML Patients

Presenter: Gert Ossenkoppele, MD, PhD

Moderator: Elias Jabbour, MD

ELDERLY/UNFIT AML PATIENTS: SELECTED ABSTRACTS (1/6)

EP556: FIVE-YEAR FINAL RESULTS OF A PHASE III STUDY OF CPX-351 vs 7+3 IN OLDER ADULTS NEWLY DIAGNOSED AML PTS J.E. Lancet, et al

Background

> Final 5-year follow-up analysis of the pivotal phase III study of CPX-351 (liposomal cytarabine-daunorubicin) vs conventional 7+3

ELDERLY/UNFIT AML PATIENTS: SELECTED ABSTRACTS (2/6)

S141: 10-DAY DECITABINE AND VENETOCLAX (DEC10-VEN) vs INTENSIVE CHEMOTHERAPY (IC) IN AML A. Maiti, et al

ELDERLY/UNFIT AML PATIENTS: SELECTED ABSTRACTS (3/6)

S142: COMPARATIVE RESULTS OF AZACITIDINE AND DECITABINE FROM A LARGE PROSPECTIVE PHASE 3 STUDY IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR IC A.M. Zeidan, et al

Background

ELDERLY/UNFIT AML PATIENTS: SELECTED ABSTRACTS (4/6)

S137: RESULTS FROM LI-1 TRIAL: LOW-DOSE ARA-C (LDAC) + QUIZARTINIB vs LDAC IN OLDER PATIENTS WITH AML M. Dennis, et al

EPICS

Background

> The study aims to assess the efficacy of LDAC plus quizartinib (AC220) vs LDAC alone in pts ≥60 yr unsuitable for IC, in a

ELDERLY/UNFIT AML PATIENTS: SELECTED ABSTRACTS (5/6)

S136: VIALE-C STUDY 6-MONTH UPDATE: VEN + LDAC IN PREVIOUSLY UNTREATED OLDER AML PTS A.H. Wei, et al

Background

- Phase III trial to compare the safety and efficacy of VEN or placebo (PBO) plus LDAC

ELDERLY/UNFIT AML PATIENTS: SELECTED ABSTRACTS (6/6)

LB2601: VIALE-A STUDY: VEN + AZA VS PLACEBO + AZA vs PLACEBO + AZA IN TREATMENT-NAIVE AML PTS INELIGIBLE FOR IC C. DiNardo, et al

EPICS

Background

- Phase III trial to evaluate efficacy of AZA plus VEN vs AZA plus PBO in treatment-naive AML pts ineligible for IC

ELDERLY/UNFIT AML PATIENTS: DISCUSSION (1/2)

EPICS

VIALE-A data and treatment of unfit pts with *FLT3* mutations

- There was general consensus among the experts of the VIALE-A results as very positive and representing

ELDERLY/UNFIT AML PATIENTS: DISCUSSION (2/2)

EPICS

VIALE-A and VIALE-C data and treatment of fit pts (cont)

- Another expert from the US considered as very positive the long-term follow-up data of CPX-351. The VEN

APTITUDE HEALTH®

EPICS

IDH- and *FLT3*-Mutant AML Patients

Presenter: Jorge Sierra, MD, PhD

Moderator: Elias Jabbour, MD

IDH- AND *FLT3*-MUTANT AML PATIENTS: SELECTED ABSTRACTS (1/4)

S139: ENASIDENIB +AZA IN IDH2 MUT NEWLY DIAGNOSED AML PATIENTS

C. DiNardo, et al

Background

> Open-label, randomized, multicenter phase II trial comparing enasidenib (ENA), a small-molecule inhibitor of mutant *IDH2*, in combination with

IDH- AND *FLT3*-MUTANT AML PATIENTS: SELECTED ABSTRACTS (2/4)

S140: POSTTRANSPLANT MAINTENANCE THERAPY IN AML PATIENTS WITH FLT3-MUT J.D. Griffin, et al

Background

- Retrospective chart review study to examine real-world post-HSCT maintenance therapy in adult AML pts with *FLT3*

IDH- AND *FLT3*-MUTANT AML PATIENTS: SELECTED ABSTRACTS (3/4)

S147: EMERGING MUTATIONS AT RELAPSE IN R/R AML FLT3-MUT PATIENTS WHO RECEIVED GILTERITINIB THERAPY IN THE PHASE 3 ADMIRAL TRIAL C.C. Smith, et al

Background

> NGS analysis of blood or bone marrow samples of pts who relapsed on gilteritinib therapy in the ADMIRAL trial, to evaluate

IDH- AND *FLT3*-MUTANT AML PATIENTS: SELECTED ABSTRACTS (4/4)

S148: MOLECULAR LANDSCAPE AND PROGNOSTIC IMPACT OF FLT3-ITD SITE IN AML: RESULTS FROM THE RATIFY STUDY (ALLIANCE 10603) F.G. Rücker, et al

Background

> NGS analysis performed on *FLT3*-ITD+ pts enrolled in the RATIFY trial to investigate the relationship between internal

IDH- AND *FLT3*-MUTANT AML PATIENTS: DISCUSSION (1/2)

EPICS

Treatment of AML pts with *IDH1/2* mutations

> The experts discussed what their treatment choice would be for pts with *IDH* mutation, assuming that all the

IDH- AND *FLT3*-MUTANT AML PATIENTS: DISCUSSION (2/2)

EPICS

Maintenance therapy in AML (cont)

> Some of the experts provided the following information

APTITUDE HEALTH®

EPICS

Emerging Immune Therapies in AML

Presenter: Naval Daver, MD

Moderator: Elias Jabbour, MD

EMERGING IMMUNE THERAPIES IN AML: SELECTED ABSTRACTS (1/5)

S143: IVOSIDENIB WITH VENETOCLAX +/- AZACITIDINE IN *IDH1*-MUTATED HEMATOLOGIC MALIGNANCIES C. DiNardo, et al

Background

- Phase Ib/II open-label nonrandomized study to assess the safety and efficacy of the mutant *IDH1*-targeted therapeutic

EMERGING IMMUNE THERAPIES IN AML: SELECTED ABSTRACTS (2/5)

S144: ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN AML PATIENTS N. Daver, et al

Background

- Phase Ib study to determine the safety and efficacy of the first-in-class anti-CD47 antibody magrolimab plus AZA in

EMERGING IMMUNE THERAPIES IN AML: SELECTED ABSTRACTS (3/5)

S149: FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR (CCAR) T CELL THERAPY IN R/R AML F. Liuet, et al

Background

> Phase I clinical trial to evaluate toxicity and efficacy of CLL1-CD33 cCAR in R/R AML and explore the probability of reducing

EMERGING IMMUNE THERAPIES IN AML: SELECTED ABSTRACTS (4/5)

EP582: UPDATE ON PRELIMINARY RESULTS OF AMG 330 IN R/R AML PATIENTS

F. Ravandi, et al

Background

> Phase I dose-escalation study to evaluate safety, tolerability, PK, PD, and efficacy of the bispecific T-cell engager AMG 330, which engages

EMERGING IMMUNE THERAPIES IN AML: SELECTED ABSTRACTS (5/5)

S181: APR-246 COMBINED WITH AZACITIDINE IN TP53 MUTATED MDS AND AML PATIENTS T. Cluzeau, et al

Background

- Phase II study of AZA plus APR-246 in *TP53*+ MDS and AML

EMERGING IMMUNE THERAPIES IN AML: DISCUSSION (1/4)

EPICS

Treatment of AML patients with *TP53* mutation

- In light of the presented data and emerging therapies, the experts discussed the best treatment approach for

EMERGING IMMUNE THERAPIES IN AML: DISCUSSION (2/4)

EPICS

Treatment of AML patients with *TP53* mutation (cont)

- Most of the experts prefer to reach CR before sending pts to transplant. The need for posttransplant

EMERGING IMMUNE THERAPIES IN AML: DISCUSSION (3/4)

EPICS

Treatment with bispecific T-cell engagers (cont)

MRD

EMERGING IMMUNE THERAPIES IN AML: DISCUSSION (4/4)

EPICS

Use of CAR T treatment in AML

- The experts discussed the current and future use of CAR T therapy for AML pts

APTITUDE HEALTH®

EPICS

Updates in ALL

Presenter: Josep Maria Ribera, MD, PhD

Moderator: Dieter Hölzer, MD, PhD

UPDATES IN ALL: SELECTED ABSTRACTS (1/6)

S116: VENETOCLAX AND NAVITOCLAX IN R/R ALL AND LYMPHOBLASTIC LYMPHOMA

E. Jabbour, et al

Background

- Phase I study to investigate the safety and efficacy of VEN plus navitoclax (NAV), a BCL-2/BCL-XL/BCL-W inhibitor, and

UPDATES IN ALL: SELECTED ABSTRACTS (2/6)

S117: IMPROVED OUTCOME FOR PATIENTS WITH ALL AND ABL-CLASS FUSION FOLLOWING TKI. PRELIMINARY DATA FROM UKALL 2011 A. Moorman, et al

Background

- Phase III trial to assess the frequency of ABL class fusions among pts responding slowly to induction therapy and to

UPDATES IN ALL: SELECTED ABSTRACTS (3/6)

S118: TISAGENLECLEUCEL FOR PEDIATRIC/YOUNG ADULT PTS WITH R/R B-CELL ALL WITH PREVIOUS EXPOSURE TO BLINATUMOMAB OR INOTUZUMAB AS BRIDGING THERAPY A. Baruchel, et al

Background

- Phase II single-arm study to determine the efficacy and safety of tisagenlecleucel in R/R ALL pediatric/young adults pts.

UPDATES IN ALL: SELECTED ABSTRACTS (4/6)

EP392: TUMOR BURDEN AND OUTCOME AFTER BLINATUMOMAB IN ADULTS WITH B-ALL

A. Cabannes-Hamy, et al

Background

- Retrospective study to assess the impact of pre-BLINA tumor burden on patient outcomes

UPDATES IN ALL: SELECTED ABSTRACTS (5/6)

EP401: BLINATUMOMAB USE DURING CONSOLIDATION IN ADULT PATIENTS WITH HIGH-RISK ALL: PRELIMINARY RESULTS OF THE BLIN01 TRIAL J.M. Ribera, et al

Background

- Preliminary data on safety and efficacy of BLINA use in consolidation, alternating with high-dose chemotherapy in pts with

UPDATES IN ALL: SELECTED ABSTRACTS (6/6)

ASCO2020 #10519: EVALUATION OF CD22 MODULATION AS A MECHANISM OF RESISTANCE TO INOTUZUMAB OZOGAMICIN (InO): RESULTS FROM COG AALL1621 TRIAL N.N. Shah, et al

Background

- Results of central surface CD22 expression on ALL and impact on response in pts from COG AALL1621, a phase II trial evaluating the efficacy of InO in children and young adults with R/R CD22+ B-cell ALL

UPDATES IN ALL: DISCUSSION (1/2)

EPICS

Use of transplant in Ph+ ALL

- It was noted that there are no randomized trials that have addressed the questions on the possible advantage of transplant

UPDATES IN ALL: DISCUSSION (2/2)

EPICS

Allogeneic transplant (alloHSCT) after CAR T treatment

Two different approaches were described by the experts on when they consider it beneficial to transplant their pts after CAR T

APTITUDE HEALTH®

EPICS

ABBREVIATIONS

ABBREVIATIONS

cCAR, compound chimeric antigen receptor

CIR, cumulative incidence of relapse

LDAC, low-dose ara-C

mCR, marrow CR

APTITUDE HEALTH®

US Headquarters
5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters
Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

aptitude-health.com